NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT02632448 2025-05-02A Study of LY2880070 in Participants With Advanced or Metastatic CancerEsperas Pharma Inc.Phase 1/2 Completed229 enrolled